Solvonis Therapeutics plc (GB:SVNS)
LSE:SVNS
Top Page
Solvonis Therapeutics
(LSE:SVNS)
Select Model
Select Model
Rating:50Neutral
Price Target:
0.26 p
▼(-25.71% Downside)
Action:N/ADate:01/04/26
The score is held down primarily by weak fundamentals (zero revenue in 2024, ongoing losses, and continued cash burn), despite the benefit of a low-debt balance sheet. Technical indicators are supportive (price above key moving averages with positive MACD), but missing P/E and dividend yield data limits valuation assessment.
Positive Factors
Low Leverage
Zero reported debt in 2024 and generally low leverage reduce solvency risk and lower fixed financing obligations. This durable balance-sheet strength gives management flexibility to pursue financing or strategic options without immediate refinancing pressure, a structural buffer versus leveraged peers.
Negative Factors
Zero Revenue
Revenue dropping to zero in 2024 removes the company's operating income base and eliminates margin generation. Without recurring sales, the business lacks customer validation and predictable cash inflows, making medium-term viability contingent on restoring sustainable revenue sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Zero reported debt in 2024 and generally low leverage reduce solvency risk and lower fixed financing obligations. This durable balance-sheet strength gives management flexibility to pursue financing or strategic options without immediate refinancing pressure, a structural buffer versus leveraged peers.
Read all positive factors
Solvonis Therapeutics (SVNS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£18.38M
Dividend YieldN/A
Average Volume (3M)34.43M
Price to Earnings (P/E)―
Beta (1Y)-0.99
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees3
SectorIndustrials
Sector Strength72
IndustryIndustrial - Machinery
Share Statistics
EPS (TTM)0.00
Shares Outstanding6,806,403,300
10 Day Avg. Volume23,401,787
30 Day Avg. Volume34,434,652
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-2.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Solvonis Therapeutics Business Overview & Revenue Model
Company Description
Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for co...
Solvonis Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | May 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 587.00K | 542.00K | 219.00K | 690.86K |
| Gross Profit | 0.00 | -134.00K | -51.00K | 55.00K | 517.72K |
| EBITDA | -1.38M | -2.94M | -2.59M | -900.00K | -322.29K |
| Net Income | -1.59M | -3.12M | -2.71M | -954.00K | -274.29K |
Balance Sheet | |||||
| Total Assets | 3.20M | 2.43M | 4.94M | 3.13M | 2.77M |
| Cash, Cash Equivalents and Short-Term Investments | 757.00K | 155.00K | 1.64M | 598.00K | 209.00K |
| Total Debt | 0.00 | 34.00K | 22.00K | 950.00K | 654.00K |
| Total Liabilities | 119.00K | 408.00K | 385.00K | 2.32M | 1.22M |
| Stockholders Equity | 3.08M | 2.03M | 4.55M | 812.00K | 1.54M |
Cash Flow | |||||
| Free Cash Flow | -1.13M | -1.47M | -3.08M | -255.00K | -15.00K |
| Operating Cash Flow | -1.13M | -1.24M | -2.36M | -254.00K | 1.00K |
| Investing Cash Flow | -337.00K | -232.00K | -718.00K | -1.00K | -16.00K |
| Financing Cash Flow | 2.08M | 0.00 | 4.13M | 800.00K | 199.00K |
Solvonis Therapeutics Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £6.68B | 20.02 | 24.91% | 1.29% | -0.32% | -3.96% | |
70 Outperform | £182.98M | 10.69 | 6.13% | 1.02% | 14.49% | 76.33% | |
64 Neutral | £7.49B | 15.58 | 13.46% | 1.93% | -6.93% | 18.57% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | £603.97M | 28.89 | 8.04% | 4.87% | -7.30% | -59.71% | |
61 Neutral | £75.18M | -2.99 | -13.68% | ― | 21.17% | -237.25% | |
50 Neutral | £18.38M | ― | -62.23% | ― | ― | ― |
* Industrials Sector Average
GB:SVNS
Solvonis Therapeutics
0.27
0.11
68.75%
GB:AVG
Avingtrans
550.00
225.50
69.49%
GB:IMI
IMI plc
2,754.00
1,169.85
73.85%
GB:MPAC
Mpac Group PLC
250.00
-98.50
-28.26%
GB:MGAM
Morgan Advanced Materials
218.50
46.90
27.33%
GB:SMIN
Smiths Group plc
2,463.00
809.13
48.92%
Solvonis Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Solvonis names patented PTSD drug candidate SVN‑114 as lead asset
Positive
Mar 10, 2026
Solvonis Therapeutics has selected SVN‑114 as the lead candidate in its Post‑Traumatic Stress Disorder discovery programme, following preclinical work showing balanced modulation of serotonin, dopamine and noradrenaline systems. The co...
Business Operations and StrategyProduct-Related Announcements
Solvonis Extends Novel SDRI SVN‑015 Into Depression After Positive Preclinical Results
Positive
Jan 28, 2026
Solvonis Therapeutics has expanded development of its investigational compound SVN‑015 into depression after preclinical studies in validated rodent behavioural models showed antidepressant‑like activity comparable to the widely used S...
Business Operations and Strategy
Solvonis Wins U.S. Patent Boost for Novel PTSD Drug Programme
Positive
Jan 7, 2026
Solvonis Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office covering a novel series of compounds within its SVN-SDN-14 PTSD discovery programme, bolstering the intellectual property position of this early-sta...
Business Operations and StrategyM&A Transactions
Solvonis Therapeutics Maps Out Catalyst-Rich 2026 as CNS Pipeline Gains Momentum
Positive
Dec 22, 2025
Solvonis Therapeutics reported broad progress across its CNS pipeline as it heads into what it describes as a catalyst-rich 2026, highlighting advancement of its lead alcohol use disorder (AUD) and PTSD programmes alongside AI-driven discovery eff...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.